 |
|
|
| |
Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alfa-2a (40KD), and ribavirin with or without mericitabine in HCV genotype 1-infected treatment-experienced patients with advanced hepatic fibrosis: the MATTERHORN study
|
| |
| |
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
I.M. Jacobson, D.M. Jensen, S. Pol, G.R. Foster, J.J. Feld, E. Yoshida, M. Jablkowski, H. Perez-Gomez, S. Shahdad, R. Kulkarni, M.T. Navarro, A. Scalori, J.A. Tavel, G. Hooper, N.S. Shulman, E.S. Yetzer
|
| |
|
|
|
|
|
